KDR and neoplasm: Reversion of efficient antitumor immune responses may be a significant part of the benefits of antiangiogenic therapy (in addition to the debatable “normalization of the tumor vasculature” theory) using inhibitors targeting the VEGF/VEGFR pathway (17–20).